Oh to be listed in Australia.
With solid pipeline (by Australian biotech standards), availability of R&D grants, good cash position along with assets like Inavir and Relenza, we'd shoot the lights out.
March quarter results, page-2
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
